MaxCyte: Selling ExPERT Cell Engineering Platforms

MaxCyte is a leading cell engineering platform technology to support cell therapeutic discovery, development, and commercialisation. MaxCyte’s ExPERT platform is the leading technology for non-viral ex vivo cell therapy, a market that is forecasted to grow to over $24bn by 2026.

Over the last 20 years, MaxCyte has been developing flow electroporation methods of transfection and is still operated and minority owned by the founder. The company has ~40% market share in US non-viral clinical programs and the ExPERT platforms offer better transfection rates and a faster route to clinic for customers relative to Lonza or Thermo Fisher’s competing solutions.

The company has 13 customers on strategic platform licenses where MXCT receives a recurring instrument license and consumable income per year plus a percentage of sales once the therapy is commercialised. MaxCyte is the highest-quality non-viral cell engineering globally that is positioned to be the platform provider for the future for ex vivo cell therapies.

Interview Transcript

Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.

This is a snippet of the transcript.to get full access.

Free Sample of 50+ Interviews

Or contact sales for full access

Already have an account? Sign in

Please Use PDF Download

MaxCyteMXCT

Why is MaxCyte interesting?

Related Content

Maxcyte's Technology, Pricing, & Growth Outlook

Burford & Elliott vs Argentina, CACC, SHEIN, Smurfit / WestRock, MaxCyte, Alteryx

MaxCyte: Electroporation Technology, Cell & Gene Therapy & Competition

AWS Series: Kubernetes & The Portability Illusion

Michael Carlson

Former Midwest Sales Manager at MaxCyte